Skip to main content
SpringerLink
Log in

PROMs for Gouty Arthritis

  • Chapter
  • First Online:
Patient Reported Outcome Measures in Rheumatic Diseases

  • 833 Accesses

Abstract

Patient reported outcome measures (PROMs) are important tools to measure the patients’ perspective of the health problem. Over the years, various PROMs have been developed. This chapter gives insight into the importance of PROMs in gouty arthritis and the measures as well as validation data for PROMs used in the management of gouty arthritis. Visual Analog Scale (VAS) pain is valid and reliable for acute pain measurement. Health Assessment Questionnaire (HAQ) is a valid measure of function. Short Form-36 (SF-36) is a valid measure of health-related quality of life. The use of PROMs in clinical trials of gouty arthritis is growing. However, several currently used PROMs in clinical trials are cumbersome for use in routine clinical care. Further research is needed to develop shorter versions of PROMs and test their feasibility in clinical trial studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Perez-Ruiz F, Castillo E, Chinchilla SP, Herrero-Beites AM. Clinical manifestations and diagnosis of gout. Rheum Dis Clin North Am. 2014;40(2):193–206.

    Article  PubMed  Google Scholar 

  2. Grassi W, De Angelis R. Clinical features of gout. Reumatismo. 2011;63(4):238–45.

    CAS  Google Scholar 

  3. Krishnan E. Gout and coronary artery disease: epidemiologic clues. Curr Rheumatol Rep. 2008;10(3):249–55.

    Article  CAS  PubMed  Google Scholar 

  4. Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open. 2012;2(1), e000282.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688–96.

    Article  CAS  PubMed  Google Scholar 

  6. Singh JA. When gout goes to the heart: does gout equal a cardiovascular disease risk factor? Ann Rheum Dis. 2015;74(4):631–4.

    Article  CAS  PubMed  Google Scholar 

  7. Singh JA, Yang S, Strand V, Simon L, Forsythe A, Hamburger S, et al. Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials. Ann Rheum Dis. 2011;70(7):1277–81.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Singh JA, Taylor WJ, Simon LS, Khanna PP, Stamp LK, McQueen FM, et al. Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol. 2011;38(7):1452–7.

    Article  PubMed  Google Scholar 

  9. Strand V, Khanna D, Singh JA, Forsythe A, Edwards NL. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase iii randomized controlled trials. J Rheumatol. 2012;39(7):1450–7.

    Article  CAS  PubMed  Google Scholar 

  10. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care. 2008;14(4):234–54.

    PubMed  Google Scholar 

  11. Valderas JM, Alonso J. Patient reported outcome measures: a model-based classification system for research and clinical practice. Qual Life Res Int J Qual Life Asp Treat Care Rehab. 2008;17(9):1125–35.

    Article  Google Scholar 

  12. Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, et al. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the patient-reported outcomes (pro) harmonization group meeting at the food and drug administration, February 16, 2001. Value Health. 2003;6(5):522–31.

    Article  PubMed  Google Scholar 

  13. Rothman ML, Beltran P, Cappelleri JC, Lipscomb J, Teschendorf B, Mayo FDAP-ROCMG. Patient-reported outcomes: conceptual issues. Value Health. 2007;10 Suppl 2:S66–75.

    Article  PubMed  Google Scholar 

  14. Patient Reported Outcome Measures Information System (PROMIS). Patient reported outcomes (PROs). 2015. http://www.nihpromis.org/patients/PROs.

  15. McKenna SP. Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science. BMC Med. 2011;9:86.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Bevans M, Ross A, Cella D. Patient-reported outcomes measurement information system (PROMIS): efficient, standardized tools to measure self-reported health and quality of life. Nurs Outlook. 2014;62(5):339–45.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Weldring T, Smith SM. Patient-reported outcomes (pros) and patient-reported outcome measures (proms). Health Serv Insights. 2013;6:61–8.

    PubMed  PubMed Central  Google Scholar 

  18. Valderas JM, Kotzeva A, Espallargues M, Guyatt G, Ferrans CE, Halyard MY, et al. The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literature. Qual Life Res. 2008;17(2):179–93.

    Article  CAS  PubMed  Google Scholar 

  19. Greenhalgh J, Meadows K. The effectiveness of the use of patient-based measures of health in routine practice in improving the process and outcomes of patient care: a literature review. J Eval Clin Pract. 1999;5(4):401–16.

    Article  CAS  PubMed  Google Scholar 

  20. Alvarez-Hernandez E, Pelaez-Ballestas I, Vazquez-Mellado J, Teran-Estrada L, Bernard-Medina AG, Espinoza J, et al. Validation of the health assessment questionnaire disability index in patients with gout. Arthritis Rheum. 2008;59(5):665–9.

    Article  PubMed  Google Scholar 

  21. Spaetgens B, Tran-Duy A, Wijnands JM, van der Linden S, Boonen A. Health and utilities in patients with gout under the care of a rheumatologist. Arthritis Care Res (Hoboken). 2015;67(8):1128–36.

    Article  CAS  Google Scholar 

  22. ten Klooster PM, Vonkeman HE, Voshaar MA, Bode C, van de Laar MA. Experiences of gout-related disability from the patients' perspective: a mixed methods study. Clin Rheumatol. 2014;33(8):1145–54.

    Article  PubMed  Google Scholar 

  23. Singh JA. The impact of gout on patient's lives: a study of African-American and Caucasian men and women with gout. Arthritis Res Ther. 2014;16(3):R132.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Kim SY, Choi HK. Gout and quality of life. J Rheumatol. 2009;36(5):865–8.

    Article  PubMed  Google Scholar 

  25. Singh JA. Quality of life and quality of care for patients with gout. Curr Rheumatol Rep. 2009;11(2):154–60.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;67(5):609–13.

    Article  CAS  PubMed  Google Scholar 

  27. Lindsay K, Gow P, Vanderpyl J, Logo P, Dalbeth N. The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach. J Clin Rheumatol. 2011;17(1):1–6.

    Article  PubMed  Google Scholar 

  28. Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14(1):10–5.

    Article  CAS  PubMed  Google Scholar 

  29. Kleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, et al. The impact of gout on work absence and productivity. Value Health. 2007;10(4):231–7.

    Article  PubMed  Google Scholar 

  30. Anonymous. United states bone and joint decade: the burden of musculoskeletal diseases in the united states. Chapter 4. Arthritis and related conditions. Rosemont: American Academy of Orthopaedic Surgeons; 2008.

    Google Scholar 

  31. Center for Disease Control and Prevention (CDC). Gout 2015. http://www.cdc.gov/arthritis/basics/gout.htm.

  32. Cohen SB, Strand V, Aguilar D, Ofman JJ. Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy. Rheumatology. 2004;43(6):704–11.

    Article  CAS  PubMed  Google Scholar 

  33. Lubaczewski S, Shepherd J, Fayyad R, Guico-Pabia CJ. Real-world disparities between patient- and clinician-reported outcomes: results from a disease-specific program in depression and anxiety. Prof Case Manag. 2014;19(2):63–74.

    Article  PubMed  Google Scholar 

  34. Quinten C, Maringwa J, Gotay CC, Martinelli F, Coens C, Reeve BB, et al. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst. 2011;103(24):1851–8.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Chalmers RL, Begley CG, Edrington T, Caffery B, Nelson D, Snyder C, et al. The agreement between self-assessment and clinician assessment of dry eye severity. Cornea. 2005;24(7):804–10.

    Article  PubMed  Google Scholar 

  36. Taylor WJ, Redden D, Dalbeth N, Schumacher HR, Edwards NL, Simon LS, et al. Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout. J Rheumatol. 2014;41(3):574–80.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Singh JA, Taylor WJ, Dalbeth N, Simon LS, Sundy J, Grainger R, et al. OMERACT endorsement of measures of outcome for studies of acute gout. J Rheumatol. 2014;41(3):569–73.

    Article  PubMed  Google Scholar 

  38. Schumacher Jr HR, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, et al. Outcome measures for acute and chronic gout. J Rheumatol. 2005;32(12):2452–5.

    PubMed  Google Scholar 

  39. Diaz-Torne C, Pou MA, Castellvi I, Corominas H, Taylor WJ. Concerns of patients with gout are incompletely captured by OMERACT-endorsed domains of measurement for chronic gout studies. J Clin Rheumatol. 2014;20(3):138–40.

    Article  PubMed  Google Scholar 

  40. Taylor WJ. Gout measures: gout assessment questionnaire (gaq, gaq2.0), and physical measurement of tophi. Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S59–63.

    Article  Google Scholar 

  41. Colwell HH, Hunt BJ, Pasta DJ, Palo WA, Mathias SD, Joseph-Ridge N. Gout assessment questionnaire: initial results of reliability, validity and responsiveness. Int J Clin Pract. 2006;60(10):1210–7.

    Article  CAS  PubMed  Google Scholar 

  42. Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology. 2011;50(4):740–5.

    Article  PubMed  Google Scholar 

  43. Ten Klooster PM, Oude Voshaar MA, Taal E, van de Laar MA. Comparison of measures of functional disability in patients with gout. Rheumatology. 2011;50(4):709–13.

    Article  PubMed  Google Scholar 

  44. Khanna D, Ahmed M, Yontz D, Ginsburg SS, Park GS, Leonard A, et al. The disutility of chronic gout. Qual Life Res. 2008;17(5):815–22.

    Article  PubMed  Google Scholar 

  45. Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen FM. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology. 2007;46(12):1804–7.

    Article  CAS  PubMed  Google Scholar 

  46. Lanser P, Gesell S. Pain management: the fifth vital sign. Healthc Benchmarks. 2001;8(6):68–70. 62.

    CAS  PubMed  Google Scholar 

  47. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287–333.

    Article  PubMed  Google Scholar 

  48. Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007;49(5):670–7.

    Article  PubMed  Google Scholar 

  49. Schlesinger N, Detry MA, Holland BK, Baker DG, Beutler AM, Rull M, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol. 2002;29(2):331–4.

    PubMed  Google Scholar 

  50. Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839–48.

    Article  CAS  PubMed  Google Scholar 

  51. Ottaviani S, Molto A, Ea HK, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Shrestha M, Chiu MJ, Martin RL, Cush JJ, Wainscott MS. Treatment of acute gouty arthritis with intramuscular ketorolac tromethamine. Am J Emerg Med. 1994;12(4):454–5.

    Article  CAS  PubMed  Google Scholar 

  53. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009;68(10):1613–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev. 2013;4, CD009920.

    PubMed  Google Scholar 

  55. Bijur PE, Silver W, Gallagher EJ. Reliability of the visual analog scale for measurement of acute pain. Acad Emerg Med Off J Soc Acad Emerg Med. 2001;8(12):1153–7.

    Article  CAS  Google Scholar 

  56. Sivera F, Wechalekar MD, Andres M, Buchbinder R, Carmona L. Interleukin-1 inhibitors for acute gout. Cochrane Database Syst Rev. 2014;9, CD009993.

    PubMed  Google Scholar 

  57. Taylor WJ, Colvine K, Gregory K, Collis J, McQueen FM, Dalbeth N. The health assessment questionnaire disability index is a valid measure of physical function in gout. Clin Exp Rheumatol. 2008;26(4):620–6.

    CAS  PubMed  Google Scholar 

  58. Chandratre P, Roddy E, Clarson L, Richardson J, Hider SL, Mallen CD. Health-related quality of life in gout: a systematic review. Rheumatology. 2013;52(11):2031–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Hirsch JD, Gnanasakthy A, Lale R, Choi K, Sarkin AJ. Efficacy of canakinumab vs. Triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures. Int J Clin Pract. 2014;68(12):1503–7.

    Article  CAS  PubMed  Google Scholar 

  60. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology. 2007;46(9):1441–4.

    Article  CAS  PubMed  Google Scholar 

  61. Baldwin M, Spong A, Doward L, Gnanasakthy A. Patient-reported outcomes, patient-reported information: from randomized controlled trials to the social web and beyond. Patient. 2011;4(1):11–7.

    Article  PubMed  Google Scholar 

  62. Snyder CF, Aaronson NK, Choucair AK, Elliott TE, Greenhalgh J, Halyard MY, et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2012;21(8):1305–14.

    Article  PubMed  Google Scholar 

  63. Weenink JW, Braspenning J, Wensing M. Patient reported outcome measures (proms) in primary care: An observational pilot study of seven generic instruments. BMC Fam Pract. 2014;15:88.

    Article  PubMed  PubMed Central  Google Scholar 

  64. National Quality forum. Pro's in performance measurement. 2013. http://www.google.com/url?sa=t&rct=j&q=&esrc=s&frm=1&source=web&cd=2&cad=rja&uact=8&ved=0CDUQFjAB&url=http%3A%2F%2Fwww.qualityforum.org%2FPublications%2F2012%2F12%2FPatient-Reported_Outcomes_Final_Report.aspx&ei=ZHYZVar6OZLRggTtl4PICQ&usg=AFQjCNHO3drQc9orjbBdR8O9P_TqJl9r0A&bvm=bv.89381419,d.eXY.

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Alabama at Birmingham, 510 20th Street South, FOT 805B, Birmingham, AL, 35294, USA

    Jasvinder Singh & Nipam Shah

Authors
  1. Jasvinder Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nipam Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jasvinder Singh .

Editor information

Editors and Affiliations

  1. Honorary Senior Clinical Lecturer, King’s College London, London, United Kingdom

    Yasser El Miedany

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Singh, J., Shah, N. (2016). PROMs for Gouty Arthritis. In: El Miedany, Y. (eds) Patient Reported Outcome Measures in Rheumatic Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-32851-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-32851-5_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-32849-2

  • Online ISBN: 978-3-319-32851-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation